Cost-effectiveness research in osteoporosis

Drug Development Research

Volumn 49, Issue 3, 2000, Pages 135-140

  Coyle, Douglas ^a,b   Cranney, A ^a,b   Lee, K M ^a   Welch, V ^a   Tugwell, P ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Economic evaluation; Hormone replacement therapy; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; HORMONE; VITAMIN D;

CANADA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; EXPERIMENTAL MODEL; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; OSTEOPOROSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SCREENING TEST;

EID: 0034036051     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(200003)49:3<135::AID-DDR3>3.0.CO;2-7     Document Type: Review

References (31)

1. Ankjaer-Jensen A, Johnell O. 1996. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 6:265-275.
2. Barrett-Connor E. 1998. Hormone replacement therapy. Br Med J 317:457-461.
3. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, Altman R, Brandt K, Dougados M, Lequesne M. 1997. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 24:799-802.
4. Cheung AP, Wren BG. 1992. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 156:312-316.
5. Clark AP, Schuttinga JA. 1992. Targeted estrogen/progesterone replacement therapy for osteoporosis: calculation of health care cost savings. Osteoporos Int 2:195-200.
6. Coyle D, Cranney A, Lee KM, Welch V, Tugwell P. 1999. Cost-effectiveness of nasal calcitonin in postmenopausal women. Using Cochrane collaboration methods in economic evaluation. Ann Meet Int Soc Technol Assess Health Care. 15:58.
7. Cranney A, Coyle D, Welch V, Lee KM, Tugwell P. 1999. A review of economic evaluations in osteoporosis. Arthritis Care Res 12:425-434.
8. Daly E, Roche M, Barlow D, et al. 1992. HRT: an analysis of benefits, risks and costs. Br Med Bull 48:368-400.
9. Daly E, Vessey M, Barlow D, Gray A, McPherson K, Roche M. 1996. Hormone replacement therapy in a risk-benefit perspective. Maturitas 23:247-259.
10. Drummond MF, Torrance G, Mason J. 1993. Cost-effectiveness league tables: more harm than good? Soc Sci Med 37:33-40.
11. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. 1997. Methods for the economic evaluation of health care programmes, 2nd ed. Oxford: Oxford University Press.
12. Francis RM, Anderson FH, Torgerson DJ. 1995. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 34:1167-1171.
13. Geelhoed E, Harris A, Prince R. 1994. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health 18:153-160.
14. Goerce R, O'Brien B, Pettitt D, Cuddy L, Ferraz M, Adachi J. 1996. An assessment of the burden of illness due to osteoporosis in Canada. J SOGC 18(Suppl.):15-24.
15. Jonsson B, Christiansen C, Johnell O, Hedlbrandt J. 1995. Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136-142.
16. Kristiansen IS, Falch JA, Andersen L, Aursnes I. 1997. Use of alendronate in osteoporosis - is it cost-effective? Tidsskr Nor Laegeforen 117:2619-2622.
17. NOF (National Osteoporosis Foundation). 1998. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis, status report. Osteoporos Int 4:S1-S88.
18. Norlund A. 1996. Prevention of osteoporosis - a cost-effectiveness analysis regarding fractures. Scand J Rheumatol Suppl 103:42-45.
19. OTA (Office of Technology Assessment). 1995. Cost-effectiveness analysis. US Office of Technology Assessment.
20. Papadimitroupoulos EA, Coyte PC, Josse RG, Greenwood CE. 1997. Current and projected rates of hip fractures in Canada. Can Med Assoc J 157:1537-1566
21. Torgerson D, Kanis JA. 1995. Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. Q J Med 88:135-139.
22. Torgerson DJ, Reid DM. 1999. The pharmacoeconomics of hormone replacement therapy. Pharmacoeconomics 16:9-16.
23. Torgerson D, Donaldson C, Reid D. 1996. Using economics to prioritize research: a case study of randomized trials for the prevention of hip fractures due to osteoporosis. J Health Serv Res Policy 1:141-146.
24. Torrance GW, Feeny DH. 1989. Utilities and quality adjusted life years. Int J Technol Assess Health Care 5:559-575.
25. Tosteson AN, Weinstein MC. 1991. Cost-effectiveness of hormone replacement therapy after the menopause. Bailliere Clin Obst Gyn 5:943-957.
26. Tosteson AN, Rosenthal DI, Melton LJ, Weinstein MC. 1990. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry, and hormone replacement therapy. Ann Intern Med 113:594-603
27. Van der Loos M, Paccaud F, Gutzwiller F, Chrzanowski R. 1988. Impact of hormonal prevention on fractures of the proximal femur in postmenopausal women: a simulation study. Soz Praventivmed 33:162-166.
28. Visentin P, Ciravegna R, Fabris F. 1997. Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26:185-192.
29. Weinstein MC. 1980. Estrogen use in postmenopausal women - costs, risks, and benefits. N Engl J Med 303:308-316.
30. Weinstein MC, Schiff I. 1983. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 38:445-455.
31. Weinstein MC, Tosteson AN. 1990. Cost-effectiveness of hormone replacement. Ann NY Acad Sci 592:162-172.